Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1584562 | 0.77 | P2RX7 (0.33) | P2RX7 | |
| SCHEMBL26134297 | 0.73 | LMNA (0.39) | POLB | |
| SCHEMBL2487318 | 0.67 | LMNA (0.34) | POLB | |
| SCHEMBL5500403 | 0.67 | PIK3CD (0.59) | PIK3CDPOLBHDAC1 | |
| SCHEMBL3325115 | 0.66 | HTT (0.39) | — | |
| SCHEMBL1817592 | 0.65 | RIPK1 (0.33) | — | |
| SCHEMBL23328819 | 0.64 | PIK3CD (0.65) | PIK3CDPOLBHDAC1P2RX7 | |
| SCHEMBL16333050 | 0.64 | PER2 (0.36) | PIK3CD | |
| SCHEMBL16333165 | 0.64 | PER2 (0.36) | PIK3CD | |
| SCHEMBL16333051 | 0.64 | PER2 (0.36) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703947-B2 | Compounds for treatment of Alzheimer's disease | PURDUE RESEARCH FOUNDATION (US) | 2014-04-22 | — | — | US | disclosed |
| US-20110195978-A1 | COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | PURDUE RESEARCH FOUNDATION (US) | 2011-08-11 | — | — | US | disclosed |
| EP-2349308-A1 | COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | Purdue Research Foundation (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010042796-A1 | COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | PURDUE RESEARCH FOUNDATION (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195978-A1 | COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | PSEN2, PSEN1, CHAT | PIK3CD 3249/4885POLB 1818/4885HDAC1 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.